Goldman Sachs initiates Edgewise Therapeutics stock with Neutral rating
NeutralFinancial Markets

Goldman Sachs has initiated coverage of Edgewise Therapeutics, assigning it a Neutral rating. This move is significant as it reflects the investment bank's cautious stance on the company's potential in the market. Investors will be watching closely to see how Edgewise navigates its growth strategy and responds to market conditions.
— Curated by the World Pulse Now AI Editorial System